VIMIAN GROUP AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.05 SEK | +2.21% |
|
-3.69% | +1.52% |
| Mar. 28 | Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss | DJ |
| Mar. 19 | Nordic Stocks Decreased Tuesday; Autostore Holdings Posted Biggest Loss | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 390.36 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 42.94 times its current sales, is high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.52% | 1.44B | - | ||
| -19.09% | 72.97B | B+ | ||
| -8.93% | 6.69B | B- | ||
| +21.38% | 3.6B | B- | ||
| -16.99% | 1.34B | B | ||
| -3.81% | 1.25B | - | ||
| -26.05% | 1.24B | C- | ||
| -12.71% | 1.15B | - | ||
| -4.03% | 1.01B | - | ||
| -23.05% | 817M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VIMIAN Stock
- Ratings Vimian Group AB
